오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

actor pharmaceuticals pty ltd - tibolone, quantity: 2.5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; ascorbyl palmitate; magnesium stearate; potato starch - indications ? short-term treatment of symptoms resulting from the natural or surgical menopause in postmenopausal women.,? second line therapy for the prevention of bone mineral density loss in postmenopausal women at high risk of future osteoporotic fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of bone mineral density loss.,after careful selection of users, tibogen should be prescribed for the shortest duration consistent with treatment goals. review the need for continuation of treatment after 6 months, taking into account the risk-benefit ratio for the individual user at the moment (including cardiovascular disease and breast cancer, refer clinical trials and precautions). tibogen should only be continued for as long as the benefit outweighs the risks.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - regorafenib, quantity: 40 mg - tablet - excipient ingredients: polyvinyl alcohol; croscarmellose sodium; iron oxide red; microcrystalline cellulose; povidone; purified talc; magnesium stearate; titanium dioxide; macrogol 3350; colloidal anhydrous silica; iron oxide yellow; lecithin - stivarga is indicated for the treatment of patients with metastatic colorectal cancer (crc) who have been previously treated with fluoropyrimidine,- oxaliplatin- and irinotecan-based chemotherapy, an anti-vegf therapy, and, if ras wild type, an anti-egfr therapy.,stivarga is indicated for the treatment of patients with unresectable or metastatic gastrointestinal stromal tumours (gist) who progressed on or are intolerant to prior treatment with imatinib and sunitinib.,stivarga is indicated for the treatment of patients with hepatocellular carcinoma (hcc) who have been previously treated with sorafenib.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - anastrozole, quantity: 1 mg - tablet, film coated - excipient ingredients: sodium starch glycollate type a; titanium dioxide; macrogol 6000; hypromellose; macrogol 400; magnesium stearate; povidone; lactose monohydrate - early breast cancer adjuvant treatment of early breast cancer in postmenopausal women with oestrogen/progesterone-receptor-positive disease. advanced breast cancer first line treatment of advanced breast cancer in postmenopausal women with oestrogen/progesterone-receptor-positive disease. treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. patients with oestrogen-receptor-negative disease and patients who have not responded to previous tamoxifen therapy rarely respond to anastrozole.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - anastrozole, quantity: 1 mg - tablet, film coated - excipient ingredients: sodium starch glycollate; titanium dioxide; lactose monohydrate; magnesium stearate; hydrogenated cottonseed oil; hypromellose; macrogol 6000; pregelatinised maize starch; povidone - early breast cancer. adjuvant treatment of early breast cancer in postmenopausal women with oestrogen/progesterone receptor positive disease. advanced breast cancer. first line treatment of advanced breast cancer in postmenopausal women with oestrogen/progesterone receptor positive disease. treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. patients with oestrogen receptor negative disease and patients who have not responded to previous tamoxifen therapy rarely respond to anastrozole.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - anastrozole, quantity: 1 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; hyprolose; magnesium stearate; microcrystalline cellulose; sodium starch glycollate type a; lactose monohydrate; titanium dioxide; hypromellose; macrogol 4000 - early breast cancer: adjuvant treatment of early breast cancer in post-menopausal women with estrogen/progesterone receptor positive disease. advanced breast cancer: first line treatment of advanced breast cancer in post-menopausal women with estrogen/progesterone receptor positive disease. treatment of advanced breast cancer in post-menopausal women with disease progression following tamoxifen therapy. patients with estrogen-receptor-negative disease and patients who have not responded to previous tamoxifen therapy rarely respond to anastrozole.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - rosuvastatin calcium, quantity: 41.581 mg - tablet, film coated - excipient ingredients: lactose monohydrate; sodium citrate dihydrate; magnesium stearate; microcrystalline cellulose; crospovidone; titanium dioxide; hypromellose; iron oxide red; macrogol 400 - rosuvastatin should be used as an adjunct to diet when the response to diet and exercise is inadequate.,prevention of cardiovascular events,rosuvastatin is indicated for prevention of major cardiovascular events in men greater than or equal to 50 years old and women greater than or equal to 60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). rosuvastatin is indicated to:,? reduce the risk of nonfatal myocardial infarction,? reduce the risk of nonfatal stroke,? reduce the risk of coronary artery revascularisation procedures.,in patients with hypercholesterolaemia,rosuvastatin is indicated for the treatment of hypercholesterolaemia (excluding heterozygous familial hypercholesterolaemia).,prior to initiating therapy with rosuvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - rosuvastatin calcium, quantity: 20.79 mg - tablet, film coated - excipient ingredients: lactose monohydrate; sodium citrate dihydrate; magnesium stearate; microcrystalline cellulose; crospovidone; titanium dioxide; hypromellose; iron oxide red; macrogol 400 - rosuvastatin should be used as an adjunct to diet when the response to diet and exercise is inadequate.,prevention of cardiovascular events,rosuvastatin is indicated for prevention of major cardiovascular events in men greater than or equal to 50 years old and women greater than or equal to 60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). rosuvastatin is indicated to:,? reduce the risk of nonfatal myocardial infarction,? reduce the risk of nonfatal stroke,? reduce the risk of coronary artery revascularisation procedures.,in patients with hypercholesterolaemia,rosuvastatin is indicated for the treatment of hypercholesterolaemia (excluding heterozygous familial hypercholesterolaemia).,prior to initiating therapy with rosuvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - rosuvastatin calcium, quantity: 5.198 mg - tablet, film coated - excipient ingredients: crospovidone; lactose monohydrate; microcrystalline cellulose; sodium citrate dihydrate; magnesium stearate; titanium dioxide; hypromellose; iron oxide yellow; macrogol 400 - rosuvastatin should be used as an adjunct to diet when the response to diet and exercise is inadequate.,prevention of cardiovascular events,rosuvastatin is indicated for prevention of major cardiovascular events in men greater than or equal to 50 years old and women greater than or equal to 60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). rosuvastatin is indicated to:,? reduce the risk of nonfatal myocardial infarction,? reduce the risk of nonfatal stroke,? reduce the risk of coronary artery revascularisation procedures.,in patients with hypercholesterolaemia,rosuvastatin is indicated for the treatment of hypercholesterolaemia (excluding heterozygous familial hypercholesterolaemia).,prior to initiating therapy with rosuvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - rosuvastatin calcium, quantity: 10.395 mg - tablet, film coated - excipient ingredients: sodium citrate dihydrate; magnesium stearate; lactose monohydrate; microcrystalline cellulose; crospovidone; titanium dioxide; hypromellose; iron oxide red; macrogol 400 - rosuvastatin should be used as an adjunct to diet when the response to diet and exercise is inadequate.,prevention of cardiovascular events,rosuvastatin is indicated for prevention of major cardiovascular events in men greater than or equal to 50 years old and women greater than or equal to 60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). rosuvastatin is indicated to:,? reduce the risk of nonfatal myocardial infarction,? reduce the risk of nonfatal stroke,? reduce the risk of coronary artery revascularisation procedures.,in patients with hypercholesterolaemia,rosuvastatin is indicated for the treatment of hypercholesterolaemia (excluding heterozygous familial hypercholesterolaemia).,prior to initiating therapy with rosuvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rosuvastatin calcium, quantity: 41.7 mg - tablet, film coated - excipient ingredients: crospovidone; magnesium stearate; colloidal anhydrous silica; lactose monohydrate; microcrystalline cellulose; titanium dioxide; hypromellose; sunset yellow fcf aluminium lake; triacetin; allura red ac aluminium lake; indigo carmine aluminium lake; iron oxide red - crosuva is indicated as an adjunct to diet when the response to diet and exercise is inadequate. prevention of cardiovascular events: crosuva is indicated for prevention of major cardiovascular events in men greater than or equal to 50 years old and women greater than or equal to 60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). crosuva is indicated to: reduce the risk of nonfatal myocardial infarction; reduce the risk of nonfatal stroke; reduce the risk of coronary artery revascularisation procedures. in patients with hypercholesterolaemia: crosuva is indicated for the treatment of hypercholesterolaemia (including familial hypercholesterolaemia). prior to initiating therapy with crosuva, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.